CN101166524B - 氨基酸衍生物 - Google Patents

氨基酸衍生物 Download PDF

Info

Publication number
CN101166524B
CN101166524B CN2006800141982A CN200680014198A CN101166524B CN 101166524 B CN101166524 B CN 101166524B CN 2006800141982 A CN2006800141982 A CN 2006800141982A CN 200680014198 A CN200680014198 A CN 200680014198A CN 101166524 B CN101166524 B CN 101166524B
Authority
CN
China
Prior art keywords
formula
compound
compounds
pain
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800141982A
Other languages
English (en)
Chinese (zh)
Other versions
CN101166524A (zh
Inventor
S·R·格雷厄姆
S·J·曼特尔
D·J·罗森
J·B·施瓦茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Original Assignee
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36677128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101166524(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd Great Britain filed Critical Pfizer Ltd Great Britain
Publication of CN101166524A publication Critical patent/CN101166524A/zh
Application granted granted Critical
Publication of CN101166524B publication Critical patent/CN101166524B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
CN2006800141982A 2005-04-28 2006-04-19 氨基酸衍生物 Expired - Fee Related CN101166524B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67602505P 2005-04-28 2005-04-28
US60/676,025 2005-04-28
PCT/IB2006/001086 WO2006114707A1 (en) 2005-04-28 2006-04-19 Amino acid derivatives

Publications (2)

Publication Number Publication Date
CN101166524A CN101166524A (zh) 2008-04-23
CN101166524B true CN101166524B (zh) 2010-12-22

Family

ID=36677128

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800141982A Expired - Fee Related CN101166524B (zh) 2005-04-28 2006-04-19 氨基酸衍生物

Country Status (26)

Country Link
US (1) US7612226B2 (enExample)
EP (1) EP1879567A1 (enExample)
JP (2) JP4173909B1 (enExample)
KR (1) KR100925900B1 (enExample)
CN (1) CN101166524B (enExample)
AP (1) AP2007004161A0 (enExample)
AR (1) AR054441A1 (enExample)
AU (1) AU2006238933B2 (enExample)
BR (1) BRPI0609879A2 (enExample)
CA (1) CA2606353C (enExample)
CR (1) CR9472A (enExample)
DO (1) DOP2006000095A (enExample)
EA (1) EA200701852A1 (enExample)
GT (1) GT200600178A (enExample)
IL (1) IL185790A0 (enExample)
MA (1) MA29408B1 (enExample)
MX (1) MX2007010978A (enExample)
NL (1) NL1031705C2 (enExample)
NO (1) NO20076000L (enExample)
PE (1) PE20061435A1 (enExample)
SV (1) SV2008002512A (enExample)
TN (1) TNSN07400A1 (enExample)
TW (1) TW200719889A (enExample)
UY (1) UY29498A1 (enExample)
WO (1) WO2006114707A1 (enExample)
ZA (1) ZA200707678B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714980B2 (en) 1996-07-24 2000-01-13 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
BRPI0609879A2 (pt) * 2005-04-28 2010-05-11 Pfizer Ltd derivados de aminoácidos
WO2007057767A2 (en) * 2005-11-17 2007-05-24 Pfizer Limited Amino acid derivatives
WO2008031221A1 (en) * 2006-09-12 2008-03-20 Cephalin Pharmaceuticals Inc. Isovaline for treatment of pain
CN101195583B (zh) * 2006-12-04 2012-07-04 四川抗菌素工业研究所有限公司 一种光学纯米那普仑及其盐的制备方法
AU2009290988B2 (en) * 2008-09-09 2016-01-28 F. Hoffmann-La Roche Ag Polymorphs of acyl sulfonamides
JP2012176902A (ja) * 2011-02-25 2012-09-13 Tosoh F-Tech Inc 新規な光学活性含フッ素化合物、その製造方法及びそれを用いた光学活性３，３，３−トリフルオロアラニンの製造方法
AT514349B1 (de) * 2013-06-12 2018-05-15 Red Bull Gmbh Alpha-alkylierte Aminosäuren (AAAAs)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB998355A (en) * 1961-08-09 1965-07-14 Merck & Co Inc Phenylalanine derivatives

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB504209A (en) 1937-12-14 1939-04-21 Pirelli General Cable Works Improvements in or relating to electric cables
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
DE3811256A1 (de) 1988-04-02 1989-10-19 Hoechst Ag (alpha)-trifluormethylaminosaeure-derivate, verfahren zur herstellung von (alpha)-trifluormethylaminosaeure-derivaten und ihre verwendung als arzneimittel
EP0484437A4 (en) 1989-07-27 1994-06-01 Searle & Co Renal-selective prodrugs for the treatment of hypertension
FR2681067B1 (fr) * 1991-09-10 1993-12-17 Elf Sanofi Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
JPH042899A (ja) 1990-04-16 1992-01-07 Arakawa Chem Ind Co Ltd 紙用サイズ剤および該サイズ剤を用いる紙サイジング方法
FR2661909B1 (fr) 1990-05-09 1997-08-14 Inst Nat Sante Rech Med Nouveaux composes agonistes du recepteur h3 de l'histamine a usage therapeutique, compositions pharmaceutiques agissant comme agonistes dudit recepteur et procede de preparation.
JPH051002A (ja) 1991-02-15 1993-01-08 Nikko Kyodo Co Ltd α−アミノ酸の製造方法
CA2068038A1 (en) 1991-05-08 1992-11-09 Christopher Yee Enzymatic resolution of .alpha.-tertiary carboxylic acid esters
US5993775A (en) 1991-11-27 1999-11-30 Diatide, Inc. Radioactively labeled peptides comprising a single thiol moiety
GB9200210D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
US5786373A (en) 1992-10-14 1998-07-28 Merck & Co., Inc. Fibrinogen receptor antagonists
US5362747A (en) 1992-11-25 1994-11-08 Abbott Laboratories 2-nitroaryl and 2-cyanoaryl compounds as regulators of nitric oxide synthase
GB9325368D0 (en) 1993-12-10 1994-02-16 Univ Bristol Organic compounds
GB9325360D0 (en) 1993-12-10 1994-02-16 Univ Bristol Organic compounds
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
DE19533617A1 (de) 1995-09-11 1997-03-13 Degussa Neues Verfahren zur Herstellung von optisch aktiven alpha-Aminosäuren und alpha-Aminosäure-Derivaten
ES2183905T3 (es) 1995-12-20 2003-04-01 Hoffmann La Roche Inhibidores de metaloproteasa de matriz.
WO1998014208A1 (en) 1996-09-30 1998-04-09 President And Fellows Of Harvard College Reactive ligands and covalent ligand-protein complexes
US5962523A (en) 1996-10-25 1999-10-05 Discovery Laboratories, Inc. Methods of using butyric acid derivatives to protect against hair loss
JPH10333511A (ja) 1997-05-30 1998-12-18 Ricoh Co Ltd 画像除去促進液、該画像除去促進液を用いた被記録材の再生方法及び再生装置
JP4205191B2 (ja) 1997-12-26 2009-01-07 ダイセル化学工業株式会社 α−アミノニトリル誘導体及びα−アミノ酸の製造方法
CN1663559B (zh) 1998-03-11 2010-10-06 株式会社创研 皮肤健全剂
US6784202B1 (en) * 1998-04-17 2004-08-31 Prescient Neuropharma Inc. Cubane derivatives as metabotropic glutamate receptor agonists or antagonists and process for their preparation
DE69908648T2 (de) 1998-12-18 2004-05-13 Novo Nordisk A/S Kondensierte 1,2,4-thiadiazinderivate, ihre herstellung und verwendung
JP2002533318A (ja) 1998-12-22 2002-10-08 ニューロサーチ、アクティーゼルスカブ イオンチャネル調節剤
FR2788271B1 (fr) 1999-01-07 2001-02-09 Rhone Poulenc Agrochimie Nouveau procede de preparation d'aminoacides chiraux
JP2002535302A (ja) 1999-01-22 2002-10-22 ファーマコア，インコーポレイテッド 化学式１の化合物およびその誘導体の合成方法
WO2000044770A1 (en) 1999-01-28 2000-08-03 Chugai Seiyaku Kabushiki Kaisha Substituted phenethylamine derivatives
FR2791982B1 (fr) 1999-04-06 2002-12-27 Inst Nat Sante Rech Med Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques.
WO2001009117A1 (en) 1999-07-29 2001-02-08 Allellix Neuroscience Inc. Tricyclic compounds as glycine transport inhibitors
FR2796943A1 (fr) 1999-07-30 2001-02-02 Aventis Pharma Sa Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
AU5449699A (en) 1999-09-07 2001-04-10 Kabushiki Kaisha Soken Skin normalizing agents
WO2001017944A1 (en) 1999-09-07 2001-03-15 Mitsubishi Rayon Co., Ltd. Process for producing optically active aminoalcohol
JP2001081013A (ja) 1999-09-10 2001-03-27 Soken Kk 毛髪健全化剤
US7300775B2 (en) 1999-12-29 2007-11-27 Verenium Corporation Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
US6656958B2 (en) 2000-02-02 2003-12-02 Abbott Laboratories Substituted pyridine compounds useful for controlling chemical synaptic transmission
DE10121028A1 (de) 2000-05-05 2002-01-31 Basf Ag Verfahren zur Herstellung von Aldehyden
DE10121026A1 (de) 2000-05-05 2002-02-07 Basf Ag Verfahren zur Herstellung von Aldehyden
US6949658B2 (en) 2000-05-18 2005-09-27 Mitsubishi Rayon Co., Ltd. Process for producing optically active α-amino acid and optically active α-amino acid amide
WO2003011799A1 (en) 2000-07-31 2003-02-13 Brandeis University Kinetic resolutions of chirat 3- and 3-substituted carboxylic acids
DE10048715A1 (de) * 2000-09-30 2004-05-19 Grünenthal GmbH Verwendung von Aminosäure zur Behandlung von Schmerz
AUPR406901A0 (en) 2001-03-29 2001-04-26 La Trobe University Insecticide and method of controlling insects
JP4715058B2 (ja) 2001-08-02 2011-07-06 Ｊｓｒ株式会社 感放射性樹脂組成物
JP2003221328A (ja) 2002-01-29 2003-08-05 Soken Kk 皮膚健全化剤
JP2005538950A (ja) 2002-05-15 2005-12-22 ジェンザイム、コーポレーション ２−アルキルシステイン、２−（ヒドロキシル化フェニル）−４−アルキルチアゾリン−４−カルボン酸およびそれらの誘導体の合成
AU2003252536A1 (en) 2002-08-01 2004-02-23 Basf Aktiengesellschaft Pesticidal fluoroalkene derivatives
AU2003266043A1 (en) * 2002-09-13 2004-04-30 Prescient Neuropharma Inc. Xanthenyl cubane analogs with activity at the metabotropic glutamate receptors
WO2004063385A1 (ja) 2003-01-10 2004-07-29 Kaneka Corporation 光学活性α−メチルシステイン誘導体の製造方法
JP2005060311A (ja) * 2003-08-13 2005-03-10 Mochida Pharmaceut Co Ltd Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
WO2005044780A1 (ja) 2003-11-10 2005-05-19 Kyorin Pharmaceutical Co., Ltd. アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
EP1718602A4 (en) * 2004-01-30 2007-12-12 Peplin Biolipids Pty Ltd THERAPEUTIC AND CARRIER MOLECULES
GB0405289D0 (en) 2004-03-09 2004-04-21 Novartis Ag Organic compounds
TW200642687A (en) * 2005-03-01 2006-12-16 Pfizer Ltd Combinations comprising α-2-δ ligands
RU2007132865A (ru) 2005-03-01 2009-03-10 Пфайзер Лимитед (GB) Применение ингибиторов pde7 для лечения невропатической боли
CN101160285A (zh) * 2005-03-17 2008-04-09 辉瑞大药厂 适用于治疗疼痛的n-(n-磺酰氨基甲基)环丙烷甲酰胺衍生物
BRPI0609879A2 (pt) * 2005-04-28 2010-05-11 Pfizer Ltd derivados de aminoácidos
BRPI0619126A2 (pt) * 2005-12-02 2011-09-13 Pfizer Ltd derivados espirocìclicos, composição farmacêutica e usos dos mesmos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB998355A (en) * 1961-08-09 1965-07-14 Merck & Co Inc Phenylalanine derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
G. SIVAGNANAM et al.Alphamethyldopa Analgesia:Its Possible Mechanism of action.Arch.int.Pharmacodyn.277 1.1985,277(1),168-176.
G. SIVAGNANAM et al.Alphamethyldopa Analgesia:Its Possible Mechanism of action.Arch.int.Pharmacodyn.277 1.1985,277(1),168-176. *
JP特开2005-60311A 2005.03.10

Also Published As

Publication number Publication date
AU2006238933A1 (en) 2006-11-02
AR054441A1 (es) 2007-06-27
JP2009040767A (ja) 2009-02-26
EA200701852A1 (ru) 2008-04-28
KR20070116663A (ko) 2007-12-10
CA2606353A1 (en) 2006-11-02
ZA200707678B (en) 2009-08-26
US20060247291A1 (en) 2006-11-02
NL1031705A1 (nl) 2006-11-01
IL185790A0 (en) 2008-01-06
JP4173909B1 (ja) 2008-10-29
MX2007010978A (es) 2007-09-19
BRPI0609879A2 (pt) 2010-05-11
UY29498A1 (es) 2006-11-30
US7612226B2 (en) 2009-11-03
MA29408B1 (fr) 2008-04-01
CR9472A (es) 2007-12-04
TNSN07400A1 (fr) 2009-03-17
CN101166524A (zh) 2008-04-23
NO20076000L (no) 2008-01-28
CA2606353C (en) 2011-11-22
AP2007004161A0 (en) 2007-10-31
JP2008539221A (ja) 2008-11-13
GT200600178A (es) 2006-11-28
KR100925900B1 (ko) 2009-11-09
AU2006238933B2 (en) 2011-12-01
TW200719889A (en) 2007-06-01
NL1031705C2 (nl) 2007-05-08
PE20061435A1 (es) 2007-02-03
DOP2006000095A (es) 2006-10-15
WO2006114707A1 (en) 2006-11-02
SV2008002512A (es) 2008-02-08
HK1116417A1 (en) 2008-12-24
EP1879567A1 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
JP6002785B2 (ja) ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体
CN103958481B (zh) 可用于治疗的哒嗪衍生物
JP6491679B2 (ja) Ｇａｂａａ受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体
JP2009040767A (ja) アミノ酸誘導体
JP4555263B2 (ja) カルシウムチャンネルα２δサブユニットに親和性を有するプロリン誘導体
US7053122B2 (en) Therapeutic use of aryl amino acid derivatives
US20040092498A1 (en) Substituted glycine derivatives for use as medicaments
JP2008542198A (ja) β‐アミノ酸誘導体
US20050038047A1 (en) Azaquinazoline derivatives
HK1116417B (en) Amino acid derivatives
US20090227680A1 (en) Amino Acid Derivatives
EP1539687A1 (en) Substituted glycine derivatives for use as medicaments
JP2009516675A (ja) 疼痛を治療するためのイソシステイン誘導体
HK1081441B (zh) 对钙通道α-2-δ亚基具有亲合力的脯氨酸衍生物
JP2006507238A (ja) アリールアミノ酸誘導体の治療的使用
HK1200455B (en) Pyridazine derivatives useful in therapy
WO2007052134A1 (en) (2s)-2-aminomethyl-5-ethyl heptanoic acid its pharmaceutical use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1116417

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1116417

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101222

Termination date: 20140419